Lidocaine HCl and Epinephrine Bitartrate Injection

Strength: 3.5 mg
Packaging: Vial
Indication: for the treatment of adult patients with multiple myeloma (MM), as monotherapy in patients who have received at least one prior therapy and as part of combination induction therapy in previously untreated patients eligible for stem cell tran...

Strength: 10ml : 75mg
Indication: for the production of local or regional anesthesia including lumbar and caudal epidural block, peripheral nerve block, retrobulbar block, and infiltration anesthesia; and for continuous epidural infusion to provide analgesia during labor (obstetric analgesia)...

Strength: 15ml:150mg
Packaging: vial
Indication: for the treatment of advanced ovarian cancer (first-line and recurrent) and in combination with other antineoplastics for small cell lung cancer, non-small cell lung cancer, and other platinum-sensitive malignancies.

Strength: 15ml : 150mg
Packaging: vial
Indication: for the treatment of advanced ovarian cancer (first-line and recurrent) and in combination with other antineoplastics for small cell lung cancer, non-small cell lung cancer, and other platinum-sensitive malignancies.

Strength: 60mg
Packaging: vial
Indication: for the treatment of adult patients with relapsed or refractory multiple myeloma, as monotherapy or in combination with dexamethasone, lenalidomide plus dexamethasone, or daratumumab plus dexamethasone.​

CDMO for SVPs (including oncology drugs), GLP-1 drugs, anaesthetic drugs, small nucleic acid drugs, freeze-dried ODTs, tablets, and hard capsules, with 9 GMP workshops, 19 production lines in total.

Strength: 10mg, 5mg
Indication: for the treatment of moderate to severe dementia of the Alzheimer's type in patients with a diagnosis of Alzheimer's disease.
Technology: Ultra-low temperature freeze-forming oral lyophilized tablet technology, customized matrix materials and unique freezin...

Strength: 1mg, 0.5mg
Indication: for schizophrenia, acute mania/mixed episodes in Bipolar I Disorder, maintenance of Bipolar I Disorder, and irritability in autistic disorder.
Technology: Ultra-low temperature freeze-forming oral lyophilized tablet technology, customized matrix materi...

Strength: 10ml : 75mg, 10ml : 100mg
Packaging: plastic ampoule (BFS)
Indication: local or regional anesthesia including epidural, peripheral nerve block, and infiltration anesthesia, and for acute pain management via continuous epidural infusion (postoperative or obstetric analgesia)

Strength: 500mg/5mL, 1000mg/10mL
Packaging: vial, amouple
Indication: for the prevention and treatment of hemorrhagic episodes due to increased fibrinolysis (hyperfibrinolysis), including surgical and traumatic hemorrhage and postpartum hemorrhage.
Status: approved in Germany and Poland

Strength: 20mg : 1mL; 80mg : 4mL
Packaging: vial
Indication: for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, and head and neck cancer, as monotherapy or in combination regimens as appropriate.
Status: US FDA approved

Strength: 1.7 mL : 4% Articaine HCl and Epinephrine (Bitartrate)
Packaging: Cartridge
Indication: Anesthetic for dental surgery

Beijing Sunho Pharmaceutical was honored once again as one of the top 20 Chinese pharmaceutical CDMO enterprises in 2025.

On June 16, 2023, the "2023 Conference on High Quality Development of Healthcare Industry and the 8th Summit for China Pharmaceutical R&D Innovation" was held in Chongqing. This summit has created more high-value communication and cooperation opportunities for pharmaceutical companies to understand the latest cutting-edge developments in pharmaceutical preparations, promote cooperation in drug quality and new formulation development, and create a suitable and competitive R&D pipeline to enhance the market competitiveness of companies.The conference released the list of "Top 20 Chinese CDMO Enterprises in 2023". And Sunho Pharmaceutical was honored to be in the list, which is another high recognition of the industry's professionalism in the field of CDMO services. In the future, Sunho will continue to adhere to the core concept of "Self-surpassing and Co-development" to provide more professional and better services for our customers.